Trials / Terminated
TerminatedNCT01575769
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From Poland and Russia Who Completed the Global, Multinational Trial (WA19977).
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
This long-term, interventional, open-label extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients from Poland and Russia with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 study. Patients will receive RoActemra/Actemra 8 mg/kg every 4 weeks. The anticipated time on study treatment is 104 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RoActemra/Actemra (tocilizumab) | Tocilizumab 8 mg/kg every 4 weeks for 104 weeks |
Timeline
- Start date
- 2012-01-19
- Primary completion
- 2013-12-03
- Completion
- 2013-12-03
- First posted
- 2012-04-11
- Last updated
- 2018-02-09
- Results posted
- 2016-01-07
Locations
11 sites across 2 countries: Poland, Russia
Source: ClinicalTrials.gov record NCT01575769. Inclusion in this directory is not an endorsement.